PTI

Proteostasis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.120
+0.080
+7.69%
After Hours: 1.120 0 0.00% 19:13 09/25 EDT
OPEN
1.020
PREV CLOSE
1.040
HIGH
1.130
LOW
1.020
VOLUME
405.71K
TURNOVER
--
52 WEEK HIGH
4.720
52 WEEK LOW
0.7000
MARKET CAP
58.44M
P/E (TTM)
-1.3305
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Proteostasis Therapeutics, Inc. - PTI
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Proteostasis Therapeutics, Inc. ("Proteostasis" or the "Company") (Nasdaq: PTI) relating to its merger
PR Newswire · 08/28 16:50
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Proteostasis Therapeutics, Inc. (Nasdaq - PTI)
BALA CYNWYD, PA / ACCESSWIRE / August 26, 2020 / Law Office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Proteostasis Therapeutics, Inc.
ACCESSWIRE · 08/26 23:56
SHAREHOLDER ALERT: WeissLaw LLP Investigates Proteostasis Therapeutics, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Proteostasis Therapeutics, Inc. ("PTI" or the "Company") (NASDAQ: PTI) in connection with the Company's proposed merger with Yumanity Therapeutics, Inc. (
PR Newswire · 08/25 22:05
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Proteostasis Therapeutics, Inc.
Rowley Law PLLC is investigating potential securities law violations by Proteostasis Therapeutics, Inc. (NASDAQ: PTI) and its board of directors concerning the proposed acquisition of the company by Yumanity Therapeutics. Proteostasis Therapeutics stockholders will own approximately 32.5% of the combined
Business Wire · 08/25 20:41
PROTEOSTASIS THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger
Wilmington, Delaware--(Newsfile Corp. - August 25, 2020) - Rigrodsky & Long, P.A. announces that it is investigating Proteostasis Therapeutics, Inc. ("Proteostasis") (NASDAQ GS: PTI) regarding possible breaches of fiduciary duties and other violations of law related to Proteostasis' agreement
Newsfile · 08/25 17:00
SWBI, ONVO, YRCW and PTI among midday movers
Gainers: Viveve Medical (NASDAQ:VIVE) +111%. VivoPower International (NASDAQ:VVPR) +57%. Sigma Labs (NASDAQ:SGLB) +27%. FTS International (NYSEMKT:FTSI) +2
Seeking Alpha - Article · 08/25 16:47
A Quick Analysis On Proteostasis Therapeutics' (NASDAQ:PTI) CEO Salary
Meenu Chhabra has been the CEO of Proteostasis Therapeutics, Inc. (NASDAQ:PTI) since 2014, and this article will...
Simply Wall St. · 08/25 16:04
iBio and Viveve Medical among healthcare gainers; Proteostasis Therapeutics among losers
Gainers: Viveve Medical (VIVE) +113%. Orchard Therapeutics (ORTX) +27%. iBio (IBIO) +16%. Idera Pharmaceuticals (IDRA) +15%. Cutera (CUTR) +14%.Losers: Sonnet BioTherapeutics (SONN) -21%. Cancer Genetics (CGIX) -17%. Liminal BioSciences (LMNL) -16%. Proteostasis Therapeutics (PTI) -15%. Lipocine
Seekingalpha · 08/25 15:06
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTI. Analyze the recent business situations of Proteostasis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTI stock price target is 5.00 with a high estimate of 8.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 29.37M
% Owned: 56.30%
Shares Outstanding: 52.18M
TypeInstitutionsShares
Increased
11
574.60K
New
14
-2.23M
Decreased
14
699.52K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Franklin Berger
President/Chief Executive Officer/Director/Primary Contact
Meenu Chhabra
Chief Operating Officer/IR Contact Officer
Marija Zecevic
Chief Scientific Officer
Benito Munoz
Other
Geoffrey Gilmartin
Independent Director
David Arkowitz
Independent Director
Badrul Chowdhury
Independent Director
Kimberlee Drapkin
Independent Director
Emmanuel Dulac
Independent Director
Jeffery Kelly
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PTI
Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of novel therapeutics to treat cystic fibrosis (CF), and other diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company focuses on identifying therapies that restore protein function. The Company’s CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. The Company’s clinical developments include PTI-801, a third generation CFTR corrector, PTI-808, a CFTR potentiator, and PTI-428, a CFTR amplifier.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Proteostasis Therapeutics Inc stock information, including NASDAQ:PTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTI stock methods without spending real money on the virtual paper trading platform.